Delstrigo
Payments companies reported to CMS as associated with Delstrigo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Delstrigo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Delstrigo
These are the largest totals companies reported as associated with Delstrigo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Daniel Kuritzkes | Boston, MA | Internal Medicine | $8,871.28 |
| Ben Barnett | Houston, TX | Infectious Disease | $8,432.55 |
| Franco Felizarta | Bakersfield, CA | Infectious Disease | $6,555.53 |
| Michael Gottlieb | Pasadena, CA | Internal Medicine | $5,596.89 |
| Shannon Schrader | Houston, TX | Family Medicine | $5,410.67 |
| Margaret White | Houston, TX | Family | $4,608.27 |
| William Hardy | Los Angeles, CA | Internal Medicine | $4,050.01 |
| Ricky Hsu | New York, NY | Internal Medicine | $3,931.25 |
| Gary Sinclair | Dallas, TX | Internal Medicine | $3,761.12 |
| Timothy Wilkin | San Diego, CA | Infectious Disease | $3,509.78 |
Prescribed Delstrigo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.